Is Vilin Bio Med overvalued or undervalued?

As of 15 September 2025, the valuation grade for Vilin Bio Med has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. The PE ratio stands at 32.64, while the EV to EBITDA ratio is 35.16, indicating a premium valuation relative to its earnings potential. Additionally, the PEG ratio of 0.87 suggests that the stock may not be priced attractively in relation to its growth rate.
In comparison to its peers, Vilin Bio Med's valuation is higher than that of Cipla, which has a PE ratio of 23.18, and Dr. Reddy's Labs, with a PE of 19.12, both classified as attractive. This highlights the relative overvaluation of Vilin Bio Med within the pharmaceuticals and biotechnology sector. Notably, while the stock has outperformed the Sensex with a 1-year return of 42.54% compared to the Sensex's -1.13%, this strong performance does not mitigate the concerns regarding its current valuation.